PSR announced today the launch of its new service and dedicated website, OrphanIQTM. OrphanIQTM is a quick and easy way for companies involved in Orphan Drug development to ask a short question on a variety of topics without the need for setting up time-consuming agreements and contracts. Questions will be handled by the relevant expert, who will first assess whether the question can be answered without obtaining further information, and within a reasonable time-frame, and will subsequently provide a written answer.
"We often come across companies who are thinking of developing their drug according to the Orphan Drug legislation, but are unsure of some of the fundamentals they need to know to get them started," said Dr Anthony Hall, Chief Medical Officer, PSR. "OrphanIQTM provides such companies an easy and accessible way of gaining insight into this highly specialised area of Drug Development. Even when the development process is already underway, companies often have short but important questions relating, for example, to their clinical plan or to reimbursement issues."
"The launch of this service is part of PSR's continuous strategy to provide expert services for Orphan Drug development in an innovative way," said Dr Roger Legtenberg, General Manager, PSR. "The need for this service shows that, even in the non-standard environment that is Orphan Drug Development, practical and quick solutions can be provided for pharmaceutical and biotech companies, without having to put in heavy upfront investments."
About PSR - http://www.psr-group.com/clinical.php
PSR Group B.V. is a leading expert in Orphan drug development, providing the essential ingredients necessary to help its clients through the logistical and regulatory hurdles which are the hallmark of development programs for rare diseases. Our services span the planning, design and implementation of the program providing a one-stop-shop from start to finish.